Significant Ownership of ORBIMED ADVISORS LLC

Signature - Title
/s/ Carl L. Gordon - Carl L. Gordon/Member
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by ORBIMED ADVISORS LLC.

Notify me when ORBIMED ADVISORS LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of ORBIMED ADVISORS LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TRAW Traws Pharma, Inc. Common Stock 20% $1,164,061 760,824 ORBIMED ADVISORS LLC 31 Dec 2024
EWTX Edgewise Therapeutics, Inc. Common Stock 14% $234,894,152 15,252,867 ORBIMED ADVISORS LLC 09 May 2025
ELVN Enliven Therapeutics, Inc. COMMON STOCK 13% $140,468,212 7,918,163 ORBIMED ADVISORS LLC 16 Jun 2025
CRVS CORVUS PHARMACEUTICALS, INC. COMMON STOCK 10% $66,290,001 -$9,057,756 8,609,091 -12% ORBIMED ADVISORS LLC 23 Jan 2026
STTK Shattuck Labs, Inc. Common Stock, par value $0.0001 per share 10% $5,107,963 6,306,127 ORBIMED ADVISORS LLC 25 Aug 2025
ACET Adicet Bio, Inc. Common Stock, par value $0.0001 9.6% $11,974,668 14,772,598 ORBIMED ADVISORS LLC 08 Oct 2025
PMVP PMV Pharmaceuticals, Inc. COMMON STOCK 9.4% $6,965,407 4,975,291 ORBIMED ADVISORS LLC 23 Oct 2025
CMPX Compass Therapeutics, Inc. COMMON STOCK 8.9% $41,093,984 15,219,994 0% ORBIMED ADVISORS LLC 13 Aug 2025
WHWK Whitehawk Therapeutics, Inc. Common Stock, par value $0.0001 per share 8.9% $6,415,640 4,166,000 OrbiMed Advisors LLC 31 Mar 2025
SION Sionna Therapeutics, Inc. Common Stock 8.4% $44,607,706 3,704,959 ORBIMED ADVISORS LLC 10 Feb 2025
NPCE NeuroPace Inc Common Stock, par value $0.001 per share 8% $26,716,960 -$8,095,783 2,614,184 -23% OrbiMed Advisors LLC 30 Jun 2025
FBRX Forte Biosciences, Inc. Common Stock, par value $0.001 per share 8% $3,763,800 510,000 ORBIMED ADVISORS LLC 31 Dec 2024
MBX MBX Biosciences, Inc. COMMON STOCK 7.7% $118,413,222 -$11,880,750 3,637,887 -9.1% ORBIMED ADVISORS LLC 05 Feb 2026
AVBP ArriVent BioPharma, Inc. Common Stock 7.5% $66,692,036 3,027,328 ORBIMED ADVISORS LLC 11 Aug 2025
NSPR InspireMD, Inc. Common Stock, par value $0.0001 per share 7.4% $5,577,461 +$1,780,000 3,133,405 +47% ORBIMED ADVISORS LLC 31 Dec 2025
IKNA ImageneBio, Inc. COMMON STOCK 6.9% $820,179 -$7,669,269 773,754 -90% ORBIMED ADVISORS LLC 25 Jul 2025
RAPT RAPT Therapeutics, Inc. Common Stock, par value $0.0001 per share 6.6% $28,023,878 -$310,734,477 1,086,618 -92% ORBIMED ADVISORS LLC 30 Sep 2025
AVTX Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share 6.4% $20,124,735 +$3,734,085 1,187,300 +23% OrbiMed Advisors LLC 31 Dec 2025
CRBP Corbus Pharmaceuticals Holdings, Inc. Common Stock, par value $0.0001 per share 5.9% $5,307,498 718,200 OrbiMed Capital LLC 31 Dec 2024
CYBN Cybin Inc. Common Stock, no par value 4.9% 2,422,600 ORBIMED CAPITAL LLC 31 Dec 2025
TERN Terns Pharmaceuticals, Inc. Common Stock 4.8% $31,842,911 4,240,068 ORBIMED ADVISORS LLC 03 Nov 2025
IRON Disc Medicine, Inc. Common Stock 4.5% $73,382,798 1,556,369 ORBIMED ADVISORS LLC 10 Mar 2025
PASG Passage BIO, Inc. COMMON STOCK 4.2% $53,029 -$44,595 132,473 -46% ORBIMED ADVISORS LLC 22 Jul 2025
VTGN Vistagen Therapeutics, Inc. Common Stock, par value $0.001 per share 4.2% $1,213,378 1,639,700 0% ORBIMED CAPITAL LLC 31 Dec 2025
ADCT ADC Therapeutics SA Common Shares, par value CHF 0.08 per share 2.6% $11,953,949 -$765,959 3,230,797 -6% ORBIMED CAPITAL LLC 31 Dec 2025
VSTM Verastem, Inc. Common Stock, par value $0.0001 per share 2.4% $6,319,998 -$7,248,005 1,333,333 -53% ORBIMED ADVISORS LLC 30 Jun 2025
CTMX CytomX Therapeutics, Inc. Common Stock, par value $0.00001 per share 2.1% $15,160,295 -$21,224,155 3,525,650 -58% OrbiMed Advisors LLC 31 Dec 2025
XFOR X4 Pharmaceuticals, Inc Common Stock, par value $0.001 per share 1.7% $25,640 134,947 ORBIMED ADVISORS LLC 30 Jun 2025
CCCC C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share 1% $1,687,550 -$5,127,991 883,534 -75% OrbiMed Capital LLC 31 Dec 2025
XTNT Xtant Medical Holdings, Inc. COMMON STOCK 0% $0 0 ORBIMED ADVISORS LLC 10 Apr 2025

Schedules 13D/G Reported by ORBIMED ADVISORS LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.